Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.980 -0.100 (-1.64%)

Streaming Delayed Price Updated: 3:30 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Volume	229,073
Open	6.070
Bid (Size)	5.980 (300)
Ask (Size)	5.990 (500)
Prev. Close	6.080
Today's Range	5.900 - 6.070
52wk Range	4.250 - 13.68
Shares Outstanding	28,919,810
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗

December 05, 2025

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Via Stocktwits

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

November 17, 2025

From Candel Therapeutics

Via GlobeNewswire

Performance

YTD	-33.5%	-33.5%
1 Month	+33.8%	+33.8%
3 Month	+13.5%	+13.5%
6 Month	+18.9%	+18.9%
1 Year	-34.8%	-34.8%

More News

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 13, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗

October 14, 2025

Via Stocktwits

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

November 04, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 03, 2025

From Candel Therapeutics

Via GlobeNewswire

EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗

October 23, 2025

Via Benzinga

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

October 16, 2025

From Candel Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

October 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

October 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

October 03, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 29, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 17, 2025

From Candel Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 03, 2025

Via Benzinga

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

September 02, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

August 28, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Reports 88 Percent Q2 Loss Drop ↗

August 14, 2025

Via The Motley Fool

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 14, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

July 24, 2025

From Candel Therapeutics

Via GlobeNewswire

ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 16, 2025

Via Benzinga

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

July 09, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

June 24, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

June 23, 2025

From Candel Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?

Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Candel Therapeutics, Inc. - Common Stock trade on?

Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?

The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market

What is the current price of Candel Therapeutics, Inc. - Common Stock?

The current price of Candel Therapeutics, Inc. - Common Stock is 5.980

When was Candel Therapeutics, Inc. - Common Stock last traded?

The last trade of Candel Therapeutics, Inc. - Common Stock was at 12/26/25 03:30 PM ET

What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?

The market capitalization of Candel Therapeutics, Inc. - Common Stock is 172.94M

How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?

Candel Therapeutics, Inc. - Common Stock has 173M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.